A novel approach using adenosine receptor-targeting molecules to treat obesity and prediabetic conditions. This research aims to validate these molecules' effectiveness in both in vitro and in vivo settings, advancing to potential pharmaceutical formulations.
This research explores the use of adenosine receptor-targeting molecules as a promising solution for treating metabolic disorders, particularly obesity and prediabetes. The molecules are designed to interact with adenosine receptors, potentially offering a safe and effective treatment pathway for these conditions. The primary goal is to validate their efficacy and safety through comprehensive in vitro and in vivo testing, ultimately leading to the development of a suitable pharmaceutical formulation.
Key features:
The technology is currently at TRL 3, indicating active research and experimental proof of concept. Further validation in vitro and in vivo is planned to advance the readiness level.
Julius-Maximilians-Universität Würzburg is a comprehensive public research university in Bavaria with a broad academic profile and close integration with its university hospital. Industry collaborates through on-campus labs, shared core facilities, and clinical settings that enable prototyping, validation, and regulated testing. A regional technology park ecosystem and incubators link companies to faculty expertise and student talent, while a dedicated technology transfer office supports IP, licensing, and spin-outs. Research is backed by competitive funding from the German Research Foundation and the Federal Ministry of Education and Research, together with European programs and Bavarian state initiatives.